ATP2B4

Across TCGA pan-cancer cohorts, ATP2B4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATP2B4 data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ATP2B4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATP2B4 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, CCRCC, and HNSC are the cancer types where ATP2B4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.653	0.953	.002	30	view →
CCRCC	DFS	Quartile	All	0.641	0.860	.016	26	view →
HNSC	OS	Median	IV	0.595	0.833	.012	9	view →
LUAD	OS	Tertile	All	0.901	0.561	.012	7	view →
GBM	DFS	Tertile	All	0.246	0.541	.009	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATP2B4–LSCC (OS)

Open the LSCC breakdown →